After gaining US FDA approval in September 2023, nuclear medicine company Cyclopharm (ASX: CYC) has made an official entry into the country with the signing of its inaugural commercial contract for Technegas in the United States with Duke University Hospital the first institution to enter into a formal agreement to use Technegas. Technegas, an imaging
Read More
Radiopharmaceutical company Cyclopharm (ASX: CYC) is set to begin commercial sales of its lung imaging device Technegas in the US, following the Food and Drug Administration’s (FDA) stamp of approval on September 30.
Read More
There’s been a small bump in the road in Cyclopharm’s (ASX: CYC) plans to secure regulatory approval for Technegas™, their proprietary technology for lung imaging. Technegas™ comprises ultra-fine radioactive labelled carbon that is exposed to high heat to create a gas that can be inhaled by the patient. The gas allows for comprehensive imaging to
Read More
Australian medtech company Cyclopharm (ASX: CYC) is set to add the United States to the list of 59 countries which have approved Technegas®, its nuclear functional ventilation imaging agent, having lodged its New Drug Application (NDA) with the Food and Drug Administration (FDA). As the world’s largest nuclear medicine market in the world, the opportunity
Read More